

NEW CONCEPT PLATFORM TECHNOLOGY OF DRUG DEVELOPMENT FOR VARIOUS DISEASES

*Dr. Park Byoung Chul, e-mail: parkbc@nrf.re.kr
Division of National Sci. Eng. Program, National Research Foundation of Korea,
Univ. of Sci. & Tech., and KRIBB (South Korea)*

Drug development is a tedious job and it spend a lot of time and money. Many scientist and pharmaceutical companies are focused to new drug investment for inhibitors, blockers, and even accelerators to cellular signaling on life cycle. However most of them showed side effects, acquired immune resistances and limits of druggable targets. So we have been developed new paradigm of platform technology for successful drug development as target protein degradation. Those Protac and Degronimide are well known name as methods of target protein degradation strategy. With new E3-ligase and binder, we had been studied new drugs with well-known inhibitors but most of trials were failed. We have been optimized and examined those candidates *in vitro* and *in vivo* with target protein degradation strategy and finally got successful data. Now we strongly believe that this platform technology will very helpful for drug development and mankind.